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Selective cell death of latently HIV-infected
CD4+ T cells mediated by autosis inducing
nanopeptides
Gang Zhang 1, Brian T. Luk2, Xiaoli Wei2, Grant R. Campbell 1, Ronnie H. Fang2, Liangfang Zhang2 and
Stephen A. Spector 1,3
Abstract
Despite significant advances in the treatment of human immunodeficiency virus type-1 (HIV) infection, antiretroviral
therapy only suppresses viral replication but is unable to eliminate infection. Thus, discontinuation of antiretrovirals
results in viral reactivation and disease progression. A major reservoir of HIV latent infection resides in resting central
memory CD4+ T cells (TCM) that escape clearance by current therapeutic regimens and will require novel strategies for
elimination. Here, we evaluated the therapeutic potential of autophagy-inducing peptides, Tat-Beclin 1 and Tat-vFLIP-
α2, which can induce a novel Na+/K+-ATPase dependent form of cell death (autosis), to kill latently HIV-infected TCM
while preventing virologic rebound. In this study, we encapsulated autophagy inducing peptides into biodegradable
lipid-coated hybrid PLGA (poly lactic-co-glycolic acid) nanoparticles for controlled intracellular delivery. A single dose
of nanopeptides was found to eliminate latent HIV infection in an in vitro primary model of HIV latency and ex vivo
using resting CD4+ T cells obtained from peripheral blood mononuclear cells of HIV-infected patients on antiretroviral
with fully suppressed virus for greater than 12 months. Notably, increased LC3B lipidation, SQSTM1/p62 degradation
and Na+/K+-ATPase activity characteristic of autosis, were detected in nanopeptide treated latently HIV-infected cells
compared to untreated uninfected or infected cells. Nanopeptide-induced cell death could be reversed by
knockdown of autophagy proteins, ATG5 and ATG7, and inhibition or knockdown of Na+/K+-ATPase. Importantly, viral
rebound was not detected following the induction of the Na+/K+-ATPase dependent form of cell death induced by
the Tat-Beclin 1 and Tat-vFLIP-α2 nanopeptides. These findings provide a novel strategy to eradicate HIV latently
infected resting memory CD4+ T cells, the major reservoir of HIV latency, through the induction of Na+/K+-ATPase
dependent autophagy, while preventing reactivation of virus and new infection of uninfected bystander cells.
Introduction
At present, an estimated 37 million people live with
human immunodeficiency virus type-1 (HIV) infection
worldwide1. Despite the tremendous success of anti-
retroviral therapy (ART) in suppressing the virus and
changing HIV from an invariably fatal disease to a chronic
illness, current treatment strategies have failed to eradi-
cate the virus and achieve a virologic cure. Additionally,
despite prolonged virologic suppression, the dis-
continuation of ART in most cases leads to the rapid
return of viremia2–4. The difficulty in eradicating HIV
from latent reservoirs has changed the focus of much
research to be directed towards achieving a “functional
cure”. As part of a functional cure strategy, numerous
investigators are attempting strategies to reactivate HIV
from latent reservoirs (shock) followed by killing the virus.
However, the “shock and kill” approach has, to date, been
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unsuccessful because methods attempted have failed to
reactivate latent virus5.
The primary reservoirs of HIV latently infected cells are
thought to be long-lived, resting central memory CD4+
T cells (TCM), which are established early in infection,
harbor integrated proviral DNA, and fail to produce
replication-competent virus6–8. These latently infected
cells are not targeted by the immune system and ART is
ineffective in eradicating the virus. Although the precise
mechanisms that promote the long-term survival of HIV
latently infected TCM are largely unknown, it is likely that
cell death pathways are critical to cell survival, and that
anti-apoptotic proteins and modulation of autophagy play
an important role in prolonged cell survival.
Macroautophagy (referred to here as autophagy) is a
critical cyto-adaptive response to environmental stresses
including starvation, ischemia, cancer and infection9,10.
The hallmark of autophagy is a double-membraned
autophagosome that engulfs bulk cytoplasm and cyto-
plasmic organelles, such as mitochondria and endo-
plasmic reticulum11. The accumulation of
autophagosomes and autophagic proteins within a cell
represents the failure of autophagy to rescue the cell from
toxic stress12. Although the major role of autophagy is cell
survival and maintenance of cellular homeostasis, the over
induction of autophagy can lead to autophagic cell
death13,14. During initial HIV infection of host cells, there
is an induction of autophagy and HIV uses autophagy-
related proteins (ATG) to promote its own replication15.
During permissive infection, HIV down-regulates autop-
hagy to prolong cell survival. In the case of CD4+ T cells,
autophagy is dysfunctional and most infected cells die16.
However, infection of macrophages and microglial cells
leads to a balance between the levels of autophagy
required for cell survival and low-level viral replication
without killing the cell.
In addition to extending cell survival, autophagy plays a
central role in the degradation and elimination of intra-
cellular pathogens10,17–19. Our laboratory has had a par-
ticular interest in examining the role of autophagy in HIV
pathogenesis20–23, and identified that the induction of
autophagy inhibits HIV replication and promotes the
degradation of viral proteins23–26. Once HIV establishes a
productive infection, HIV Nef binds Beclin 1 resulting in
mTOR activation, TFEB phosphorylation and cytosolic
sequestration, and the inhibition of autophagy23. These
findings help to explain how HIV modulates autophagy to
promote cell survival and viral persistence, and further
establishes Beclin 1 as an important target to eliminate
latent reservoirs of HIV. The region of Beclin 1 binding to
Nef has been mapped to an 18 aa conserved region27. In
conjunction with the laboratory of Dr. Beth Levine, we
showed that a Tat-Beclin 1 fusion peptide consisting of
the Tat transduction domain and the identified region of
Beclin 1 that binds Nef is a potent inducer of autophagy27.
Additionally, we showed that pre-treatment of macro-
phages with this Tat-Beclin 1 peptide inhibits HIV
infection. Similar proteins that inhibit autophagy have
been found in other viruses. One of these, viral FLIP
(vFLIP) present in Kaposi’s sarcoma-associated herpes-
virus, herpesvirus saimiri and molluscum contagiosum
virus, was found to inhibit autophagy and cell death by
preventing Atg3 from binding and processing LC3, a
critical protein in autophagosome biogenesis28.
Liu et al. have described a novel form of autophagic cell
death that they have termed “autosis” which has unique
morphologic features, depends on cellular Na+/K+-
ATPase, and occurs during treatment with autophagy
inducing peptides, starvation and hypoxia29,30. In a pre-
vious study, we found that autophagy inducing peptides,
Tat-Beclin 1 and Tat-vFLIP-α2, exhibit robust anti-HIV
activity through induction of autophagy31. Both
autophagy-inducing peptides induce cell death through
autosis that is dependent on alteration of Na+/K+-
ATPase. Of interest, we found that intracellular delivery
of Tat-Beclin 1 and Tat-vFLIP-α2 peptides by lipid-coated
hybrid PLGA (poly lactic-co-glycolic acid) nanoparticles
can preferentially induce autosis and selectively kill
chronically infected macrophages. In this study, we fur-
ther evaluated the potential of these nanoformulated
autophagy-inducing peptides (nanopeptides) to kill
latently HIV-infected central memory CD4+ T cells (HIV-
TCM). Our findings demonstrate that nanopeptides can
induce a unique Na+/K+-ATPase dependent form of cell
death that has the potential to eliminate latently HIV-
infected TCM without reactivation of HIV replication, and
protect bystander cells.
Results
Nanopeptides preferentially kill CD4+ T memory cells with
latent infection
We have previously shown the ability of lipid-coated
hybrid PLGA nanoparticles loaded with Tat-vFLIP-α2
peptides to kill selectively HIV-infected macrophages31.
However, the most common reservoir of HIV is thought
to reside in resting central memory CD4+ T cells
(TCM)
32,33. Thus, our initial experiments were designed to
demonstrate the potential of these nanopeptides to pre-
ferentially kill HIV-TCM. Because the frequency of latently
HIV-infected CD4+ T cells in infected persons on fully
suppressive ART is extremely low, our laboratory has
adapted a primary in vitro latency model of HIV-infected
resting CD4+ central memory T cells for screening novel
anti-HIV latency altering agents34. In this model, HIV-
TCM lack both cell surface activation and cell cycle mar-
kers, do not synthesize DNA, do not proliferate, and
contain an average of 1 copy per cell of integrated HIV
DNA. Importantly, HIV can be reactivated from these
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cells using αCD3/αCD28-conjugated beads, phytohe-
magglutinin, M form (PHA-M) or interleukin 7. In the
studies presented here, we further optimized this latency
model through co-incubation with the HIV protease
inhibitor, atazanavir, and the nucleoside reverse tran-
scriptase inhibitor, tenofovir (Supplementary Fig. 1).
We formulated and characterized nanopeptides fol-
lowing our previous established protocol31. Using single
step nanoprecipitation, the formulated PLGA nano-
particles loaded Tat-Beclin 1 (NP-Beclin 1) and Tat-
vFLIP-α2 (NP-vFLIP-α2) had an average 127 nm and
147 nm in diameter, respectively (Supplementary Fig. 2).
All of the formulated nanopeptides had more than 15%
(wt:wt) loading yield, were stable in both PBS and water
over the 96 h evaluation period, and did not exhibit any
burst release of Tat-Beclin 1 or Tat-vFLIP-α2 in peptide
release kinetics studies (Supplementary Fig. 2).
To assess the ability of our nanopeptides to induce
preferential killing, NP-Beclin 1 and NP-vFLIP-α2 at
increasing concentrations were incubated with HIV-TCM
and uninfected cells. After 24 h, both nanopeptides
demonstrated a dose dependent killing of HIV-TCM. NP-
Beclin 1 treatment resulted in 43.6, 85.7, and 92.3% cell
death of HIV-TCM at 1, 5, and 10 µM, respectively.
Similarly, following NP-vFLIP-α2 treatment at the same
concentrations, we observed 36.6, 87.3, and 94.6% killing
of HIV-TCM (Fig. 1a). In contrast, uninfected TCM when
treated under the same conditions at the highest con-
centration of 10 µM of nanopeptide resulted in 11.2 and
12.9% cell killing for NP-Beclin 1 or NP-vFLIP-α2,
respectively.
Nanopeptides induced selective killing does not reactivate
HIV replication
We next evaluated whether nanopeptides would reac-
tivate infectious virus following treatment of HIV-TCM.
HIV infectious virus was assessed using the TZM-bl assay
system35. After co-culture with TZM-bl for 48 h, we did
not detect the presence of any infectious virus activated
from the HIV-TCM (Fig. 1b). These findings were further
confirmed by quantification of viral reverse transcriptase
(RT) activity in the collected supernatants from
nanopeptide-treated HIV-TCM. No increase in RT activity
was observed following administration of the
Fig. 1 Nanopeptides preferentially kill latent primary HIV-TCM cells. a At day 32 post infection (p.i.), latent HIV-TCM cells were treated with
increasing doses of NP-Beclin 1 or NP-vFLIP-α2 for 24 h. The cytotoxicity of NP-Beclin 1 and NP-vFLIP-α2 were measured by trypan blue staining.
b The collected cell culture supernatants were incubated with TZM-bl cells. After 48 h, TZM-bl cells were measured for ß-galactosidase activity. c The
collected cell culture supernatants were also tested for RT activity. Data are plotted from four different donors with means. M=Mock infection, H=
200 TCID50 HIVNL-43 virus, L= latent HIV-TCM cells, NP-S1= 10 μM nanoformulated Tat-Beclin-1 scrambled peptides, NP-S2= 10 μM nanoformulated
Tat-vFLIP-α2 scrambled peptides. RLU= relative luminescence units. F.S.= fluorescent signaling. *P < 0.05, ***P < 0.001
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nanopeptides (Fig. 1c), further confirming that our
nanopeptides kill latently infected TCM without reacti-
vating HIV replication.
Killing of latently infected CD4+ T cells is autophagy
dependent
Based on our previous research, we suspected that the
mechanism for the selective killing observed of HIV-TCM
would be dependent on an autophagy dependent form of
cell death31. In these experiments, HIV-TCM and unin-
fected TCM were treated with increasing concentrations of
nanopeptides. In HIV-TCM for both NP-Beclin 1 and NP-
vFLIP-α2, we observed a significant dose response
increase in LC3B-II while sequestosome 1 (SQSTM1/p62)
was significantly decreased indicating that autophagy was
being induced and going to completion (P < 0.001; Fig. 2).
In contrast for the HIV-uninfected TCM, except at the
highest concentration of the nanopeptides (10 μM), there
was little change in LC3B-II or SQSTM1/p62 (Fig. 2).
However, even at the highest concentration, the decrease
in SQSTM1/p62 in uninfected TCM was significantly less
than that observed in HIV-TCM (NP-Beclin 1, P < 0.01;
NP-vFLIP-α2, P < 0.01).
To further confirm the importance of autophagy in NP-
Beclin 1 and NP-vFLIP-α2 mediated cell death, we
assessed the effect of ATG5 and ATG7 silencing. Knock-
down of ATG5 and ATG7 reversed nanopeptide-induced
cell death (Fig. 3), and inhibited LC3B-II lipidation and
SQSTM1/p62 degradation further confirming that NP-
Beclin 1 and NP-vFLIP-α2 induced preferential cell death
is through an autophagy dependent mechanism.
Having demonstrated an important role of autophagy in
our nanopeptides induced killing of HIV-TCM, it was
important to exclude other potential causes of cell death
including apoptosis and necroptosis. In these experi-
ments, HIV-TCM were treated with the specific pharma-
cologic inhibitors of interest followed by exposure to
either NP-Beclin 1 or NP-vFLIP-α2 nanopeptides. We
used the pan-caspase inhibitor z-VAD-FMK for assessing
apoptosis and the RIPK1 inhibitor necrostatin-1 for test-
ing necroptosis. Treatment with either inhibitor, however,
had no effect on nanopeptide induced cell death (Fig. 4).
To further verify that the observed cell death is not due to
apoptosis or necroptosis, we assessed HIV-TCM and TCM
cultures for the presence of cleaved caspase (CASP)3.
Cleaved CASP3, the active form of CASP336,37, is induced
Fig. 2 Nanopeptides induce enhanced autophagy in latent HIV-TCM cells. a, b At day 32 p.i., HIV-TCM cells were treated with NP-Beclin 1 and NP-
vFLIP-α2, respectively for 24 h. Cell lysates were harvested for analysis of LC3B-II lipidation and SQSTM1/p62 degradation. Representative western
blots are shown. Densitometric analysis are summarized from 4 different donors and normalized to loading control ACTB. NP-S1= 10 μM
nanoformulated Tat-Beclin-1 scrambled peptides, NP-S2= 10 μM nanoformulated Tat-vFLIP-α2 scrambled peptides. *P < 0.05, **P < 0.01, ***P < 0.001
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Fig. 3 (See legend on next page.)
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by CASP8 and CASP9, and is considered a key initiator of
apoptosis, pyroptosis and necroptosis. Consistent with
our previous findings, the expression of cleaved CASP3 in
HIV-TCM or uninfected TCM was unchanged following
treatment with NP-Beclin 1 and NP-vFLIP-α2, further
supporting that the observed cell death was not related to
apoptosis and necroptosis.
Tat-Beclin 1 and Tat-vFLIP-α2 induce a Na+/K+-ATPase
dependent form of cell death, autosis
In previous studies performed by our lab and others,
Tat-Beclin 1 and Tat-vFLIP-α2 have been shown to
induce a Na+/K+-ATPase dependent form of cell death
that has been designated as autosis29–31,38. To determine
if autosis is responsible for the selective killing of HIV-
TCM, we evaluated the expression of Na
+/K+-ATPase in
nanopeptide-treated HIV-TCM (Fig. 5a). At increasing
concentrations of both nanopeptides, we observed an
increasing expression of the alpha 1 subunit of Na+/K+-
ATPase (ATP1A1), which is the critical catalytic com-
ponent for activating Na+/K+-ATPase. We also found
that both nanopeptides induced a dose dependent
increase of ATP1A1 in the mock-infected TCM. However,
comparing with the same dose of nanopeptide induced
ATP1A1 in the HIV-TCM cells, NP-Beclin 1 induced a
mean of 72.1, 76.7, and 55.4% less expression of ATP1A1
in mock-infected cells; similarly, NP-vFLIP-α2 induced
64.6, 69.1, and 75% less expression of ATP1A1 in the
mock infected cells.
To further establish that induction of the Na+/K+-
ATPase is the mechanism of cell death, we pre-treated
TCM cultures with digoxin, a known inhibitor of Na
+/K+-
ATPase, 2 h prior to exposure to either NP-Beclin 1 or
NP-vFLIP-α2. After 24 h, digoxin treated cultures
(see figure on previous page)
Fig. 3 RNA interference of ATG5 and ATG7 inhibits nanopeptide-induced autophagy dependent cell death in latent HIV-TCM cells. a, d
Lentiviral shATG5 and shATG7 transduced latently infected resting CD4+ T cells were tested for knockdown efficiency by western blot. b, e shATG5
and shATG7 transduced latent CD4+ TCM cells were challenged with 10 μM NP-Beclin 1 or 10 μM NP-vFLIP-α2 for 24 h. Autophagy was evaluated in
cell lysates by western blot. c, f Cytotoxicity of NP-Beclin 1 and NP-vFLIP-α2 was measured in cell culture supernatants. Densitometric analyses are
summarized from four different donors and normalized to loading control ACTB with means. NP-S1= 10 μM nanoformulated Tat-Beclin-1 scrambled
peptides, NP-S2= 10 μM nanoformulated Tat-vFLIP-α2 scrambled peptides. *P < 0.05, **P < 0.01, ***P < 0.001
Fig. 4 Nanopeptides induce caspase-independent cell death. a HIV-TCM cells were pretreated with 20 μM Z-VAD-FMK, 50 μM necrostatin-1, and
200 nM bafilomycin A1 for 2 h, and further challenged with 10 μM NP-Beclin 1 or 10 μM NP-vFLIP-α2 for an additional 24 h. The cell culture
supernatants were collected for LDH cytotoxicity assay. b Cleaved CASP3 was analyzed in the harvested cell lysates by western blot. All densitometric
analyses are summarized from four different donors and normalized to loading control ACTB with means. NP-S1= 10 μM nanoformulated Tat-Beclin
1 scrambled peptides, NP-S2= 10 μM nanoformulated Tat-vFLIP-α2 scrambled peptides. *P < 0.05, **P < 0.01, ***P < 0.001
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demonstrated a marked reduction in cell death (Fig. 5b, c).
Digoxin treated cultures also showed a marked reduction
in autophagic flux as demonstrated by the absence of
SQSTM1/p62 degradation. A similar effect was observed
in experiments where ATP1A1 was knocked down using
shRNA (Fig. 6). In total, these findings confirm that Na+/
K+-ATPase is essential to Tat-Beclin 1 and Tat-vFLIP-α2
induced TCM cell death.
HIV infection increases Na+/K+-ATPase in CD4+ T memory
cells with acute and latent infection
Recently, cardiac glycosides/aglycones which inhibit
Na+/K+-ATPase were identified to inhibit HIV replica-
tion39–41. Combined with our findings presented here, we
hypothesized that cells latently infected with HIV might
have increased Na+/K+-ATPase activity that contributes
to the generation of latency. For these experiments,
Fig. 5 NP-Beclin 1 and NP-vFLIP-α2 kills latent HIV-TCM cells through a Na
+/K+-ATPase dependent mechanism. a HIV-TCM were incubated
with increasing concentrations of NP-Beclin 1 or NP-vFLIP-α2 for 24 h. The collected cell lysates were tested for Na+/K+-ATPase-α1 subunit (ATP1A1)
expression by western blot. b After pretreating with 50 nM digoxin for 2 h, latent HIV-TCM were incubated with NP-Beclin 1 or NP-vFLIP-α2 for 24 h.
The cytotoxicity was monitored by LDH assay. c Autophagy activity was analyzed in collected cell lysates by western blot. All densitometric analyses
are summarized from four different donors and normalized to loading control ACTB with means. NP-S1= 10 μM nanoformulated Tat-Beclin-1
scrambled peptides, NP-S2= 10 μM nanoformulated Tat-vFLIP-α2 scrambled peptides. *P < 0.05, **P < 0.01, ***P < 0.001
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HIV-TCM were established and evaluated for the presence
of ATP1A1. Of interest, as the replication of virus in TCM
progressed to latency, the amount of ATP1A1 detected
steadily increased over 30 days (Fig. 7a). To explore the
potential function of Na+/K+-ATPase in generating HIV-
TCM, we incubated Na
+/K+-ATPase inhibitor digoxin
with HIV-infected CD4+ T cells, and maintained digoxin
treatment throughout the 30 days as the infection pro-
gressed to latency. As the infection progressed, the pro-
duction of HIV p24 was significantly lower in the digoxin
treated cells (Fig. 7b). When treated and untreated cul-
tures reached latency, those cells treated with digoxin had
a mean of 0.2 copies of proviral DNA per cells compared
to 1.3 of HIV-TCM controls (Fig. 7c).
Nanopeptides preferentially kill ex vivo latent CD4+ T cells
in patient blood
To confirm that nanopeptides can preferentially kill
HIV latently infected cells, we performed ex vivo studies
on patient samples. PBMC were obtained from the blood
of HIV-infected patients with viral suppression on ART,
had undetectable viral loads defined as <20 copies HIV
RNA/ml for at least 12 months and a CD4+ count of
>400/mm3. Resting CD4+ T cells were isolated from
PBMC and treated with nanopeptides for 24 h following
the methods previously described by our laboratory34.
Following treatment, there was no discernable increase in
the number of dead cells in treated versus control cul-
tures. This is not surprising given that latently infected
cells comprise <10 per 106 cells in vivo (Fig. 8a, b).
To identify the elimination of HIV latently infected cells
that produce replication competent virus, the quantitative
viral outgrowth assay (QVOA) was used34. Resting CD4+
T cells were isolated and treated with nanopeptides for
24 h, and CD4+ T cells were serially diluted and subjected
to a limiting dilution quantitative outgrowth assay. Fol-
lowing a single treatment of NP-Beclin 1 and NP-vFLIP-
α2, the amount of replication competent virus was
reduced 70.8 and 71.8%, respectively (Fig. 8c), whereas the
scrambled control nanopeptides had no effect. Thus,
these findings provide further evidence that Tat-Beclin 1
and Tat-vFLIP-α2 have the potential to preferentially
Fig. 6 Knockdown of Na+/K+-ATPase inhibits NP-Beclin 1 and NP-vFLIP-α2 induced killing of latent HIV-TCM cells. a HIV HIV-TCM cells were
transduced with shATP1A1 for knockdown of Na+/K+-ATPase. The knockdown efficiency was evaluated by western blot in cell lysates. b shATP1A1
transduced latent HIV-TCM cells were treated with 10 μM NP-Beclin 1 or 10 μM NP-vFLIP-α2 for an additional 24 h. The effect of shATP1A1 transduction
was tested by western blot in cell lysates. c Cytotoxicity was measured by LDH assay. All densitometric analyses are summarized from four different
donors and normalized to loading control ACTB with means. NP-S1= 10 μM nanoformulated Tat-Beclin-1 scrambled peptides, NP-S2= 10 μM
nanoformulated Tat-vFLIP-α2 scrambled peptides. **P < 0.01, ***P < 0.001
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eliminate HIV latently infected cells with minimal cyto-
toxicity to uninfected cells in vivo.
Inhibition of Na+/K+-ATPase prevents nanopeptide
induced killing of ex vivo patient HIV latent CD4+ T cells
To determine the mechanism of nanopeptide mediated
preferential killing of patient latently infected CD4+
T cells, we tested whether the decline in replication
competent virus was dependent on the induction of Na+/
K+-ATPase leading to autosis. For these studies, patient
resting CD4+ T cells were incubated with digoxin for 2 h
followed by treatment with nanopeptides for an additional
24 h at which time replication competent virus was
assessed by QVOA. Following digoxin treatment, the anti-
HIV and cell killing of latently infected cells of NP-Beclin
1 and NP-vFLIP-α2 was reversed and little difference was
found in the quantity of infectious virus between the
untreated and digoxin plus nanopeptide treated patient
(Supplementary Fig. 3). Thus, these results confirm that
our nanopeptides induce a Na+/K+-ATPase dependent
cell death that can be reversed by inhibiting the Na+/K+-
ATPase.
Discussion
Considerable data support that HIV infection induces
apoptosis in activated CD4+ T cells, impairing host
immune function42–46. However, in some cells, HIV alters
the transcriptional profile to promote the upregulation of
anti-apoptotic proteins, leading to prolonged cell survi-
val47–51. Additionally, during permissive infection, HIV
Nef binds to Beclin 1, a key protein in autophagy,
resulting in the down-regulation of autophagy that can
lead to the prevention of autolysosomal degradation of the
virus23,52. We have previously demonstrated that treat-
ment of macrophages with Tat-Beclin 1 and Tat-vFLIP-α2
triggers the selective killing of HIV-infected macrophages
while sparing uninfected macrophages31. However, a
primary site of the HIV reservoir in persons on ART is
believed to reside in long-lived, resting memory CD4+
T cells. Thus, in the current work, we have focused our
research on this cell population. Our findings demon-
strate both in an in vitro model and ex vivo studies that
NP-Beclin 1 and NP-vFLIP-α2 can induce the selective
killing of latent HIV-infected resting memory CD4+
T cells, while sparing uninfected cells and preventing new
infection of bystander cells. Our research has further
shown that the preferential killing of cells latently infected
with HIV is due at least in part to the increased sensitivity
of infected cells to alterations in the Na+/K+-ATPase,
driving cells to a specific form of autophagy mediated cell
death, autosis.
Numerous HIV cure strategies are currently under
investigation. Although transplantation with CCR5Δ32
homozygous hematopoietic stem cells appears to have
resulted in an HIV cure for one or two patients53–55, this
strategy is impractical and has only been applied to
Fig. 7 HIV infection increases Na+/K+-ATPase in CD4+ resting memory T cells. a ATP1A1 expression level was measured by western blot of cell
lysates of CD4+ T memory cells. b CD4+ T cells were pretreated with 50 nM digoxin for 2 h followed by infection with HIVNL-43 (M.O.I= 0.1). The
infected CD4+ T cells were incubated with 50 nM digoxin for 12 days. The cell culture supernatants were tested for HIVp24 by ELISA. c At day 12 p.i,
digoxin treated CD4+ T cells under went magnetic negative selection to enrich for central memory CD4+ T cells. The purified CD4+ T memory cells
were treated with 50 nM digoxin, 100 nM atazanavir, and 200 nM tenofovir for another 20 days. The harvested cells were measured for integrated HIV
DNA using Alu-gag QPCR. All analyses are summarized from four different donors and normalized to loading control ACTB with mean. *P < 0.05, ***P
< 0.001
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patients with malignancies. Gene therapy approaches, on
the other hand, are attempting to mimic this strategy
using zinc finger nucleases to target CCR5 and more
recently clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas-956-61. Other gene editing approa-
ches are attempting to use host restriction factors to
engineer cells to resist HIV infection. Additional strategies
aimed at reactivating HIV from latently infected cells
using latency reversing agents in what has been termed
the “shock and kill” approach whereby virus is reactivated
and subsequently killed by antiretrovirals, and in some
cases, combined with broadly neutralizing antibodies5,62.
Numerous other approaches are attempting to modulate
the immune response to HIV to control infection without
the need for antiretroviral treatment in order to achieve
what has been term a “functional cure”. Here, we have
developed a novel approach that is capable of preferential
killing HIV latently infected cells while sparing uninfected
cells. This approach is based on several important prin-
ciples: (1) Autophagy is essential for the maintenance of
cellular homeostasis and persistence of HIV latent reser-
voirs; (2) Despite being an essential survival mechanism,
excessive levels of autophagy are able to induce autophagy
dependent cell death; (3) Autosis is an autophagy-
dependent non-apoptotic form of cell death and can be
triggered by autophagy-inducing peptides through the
induction of Na+/K+-ATPase; and (4) The induction of
autosis in addition to killing cells with replicating HIV,
can kill HIV latently infected cells that are not undergoing
viral replication without reactivation of virus.
Resting CD4+ TCM cells, carrying replication-
competent latent proviral DNA, are widely considered
to remain at a quiescent status over years only to produce
HIV upon activation. Although the role of autophagy in
the establishment of HIV latent infection in resting CD4+
TCM cells is unknown, many studies have shown that
autophagy is essential for generating T memory cells and
maintaining its immune function63–65. In memory CD8+
T cells, depletion of ATG5 and ATG7 directly induces cell
death and impairs the memory phenotype66. Our previous
studies have identified the antiviral effect of autophagy in
controlling HIV infection in human primary macrophages
and memory CD4+ T cells, through the formation of
autophagosome and autolysosome mediated capture and
Fig. 8 Nanopeptides reduce HIV latent infection in resting CD4+ T cells from HIV patients ex vivo. a HIV-infected patients who were receiving
suppressive antiretroviral treatment, were virologically suppressed for >12 months (<20 copies HIV RNA/μL) and had >400 CD4+ cell/mL were
recruited for blood donation. The purified resting CD4+ T cells were treated with 10 μM NP-Beclin 1 or 10 μM NP-vFLIP-α2 for 24 h, and then activated
by PHA and γ-irradiation. Replication competent virus reactivated from CD4+ T cells was measured using a quantitative viral outgrowth assay (QVOA).
b The cytotoxicity of NP-Beclin 1 and NP-vFLIP-α2 were tested with trypan blue staining in the purified patient resting CD4+ T cells after 24 h
treatment. c The QVOA results were determined by HIVp24 ELISA and analyzed by maximum likelihood statistics. Data are summarized from seven
different donors and plotted with means. IUPM= infectious units per million resting CD4+ T cells, NP-S1= 10 μM nanoformulated Tat-Beclin-1
scrambled peptides, NP-S2= 10 μM nanoformulated Tat-vFLIP-α2 scrambled peptides. **P < 0.01
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degradation of viral proteins24–26,31,34. In this study, we
further identify that autophagy-inducing peptides have
the potential to eliminate HIV latent infection in TCM
cells using an autophagy-dependent mechanism.
To improve the translational potential of our approach,
we have loaded the autophagy-inducing peptides into
lipid-coated hybrid PLGA nanoparticles using bio-
compatible and biodegradable materials. Combining the
unique features of liposomes and polymeric nanoparticles,
our lipid-coated hybrid PLGA nanoparticles are capable
of effective delivery of encapsulated cargos67. In this
study, we successfully loaded Tat-Beclin 1 or Tat-vFLIP-
α2 into the hybrid nanoparticles resulting in sustained
release of autophagy-inducing peptides over 96 h. This
lipid hybrid PLGA nanoformulation has been shown to
extend the bioavailability of autophagy-inducing peptides
in human macrophages for almost one week in our pre-
vious study31. Indeed, the hybrid nanoparticles have
improved the intracellular bioavailability of our peptides
to HIV-infected cells, and transformed the encapsulated
peptide drug into biocompatible and translational drug
candidate68. Recently, we developed a novel targeted
version of the PLGA nanoparticles with surface coating of
CD4+ T cell plasma membrane, which broadly recognizes
HIV envelope protein, glycosylated protein 120 (gp120)69.
This CD4+ T cell plasma membrane coated polymeric
nanoparticle has high binding affinity to HIV gp120
leading to robust antiretroviral activity through neu-
tralizing cell free HIV entering into CD4+ T cells and
macrophages. This new formulation has the potential to
improve the targeted killing of all HIVgp120 positive cells
including chronically infected and reactivated latently
infected cells.
In summary, we have identified that two nanopeptides,
Tat-Beclin 1 and Tat-vFLIP-α2, targeting proteins critical
to autophagy induce Na+/K+-ATPase and selectively kill
HIV latently infected resting memory CD4+ T cells with
little effect on uninfected cells. The preferential killing of
latently infected cells is dependent on increased Na+/K+-
ATPase as the induction of cell death can be reversed by
digoxin, an inhibitor of Na+/K+-ATPase. These peptides
when loaded into PLGA nanoparticles can be delivered
and incorporated into HIV-infected cells, and are syn-
thesized from FDA-approved material that will facilitate
their ability to be used in humans. Thus, we believe that
these peptides have great potential to be used as part of an
overall strategy designed to eliminate HIV from infected
persons.
Materials and methods
Ethics statement
Venous blood was obtained from HIV seronegative and
HIV seropositive donors. The protocol was reviewed and
approved by the Human Research Protections Program of
the University of California, San Diego (Project 09-0660).
Written informed consent was obtained from all blood
donors.
Preparation of NP-Beclin 1 and NP-vFLIP-α2
Autophagy-inducing peptides including Tat-Beclin 1
(RRRQRRKKRGY-GG-TGFEGDHWIEFTANFVNT), scr-
ambled Tat-Beclin 1 (RRRQRRKKRGY-GG-WETAFGT-
TEHNIFFDNGV), Tat-vFLIP-α2 (RRRQRRKKRGY-GFVN
LLFLVVE) and scrambled Tat-vFLIP-α2 (RRRQRRKKRGY-
GFVNLAAAVVE), were synthesized in D-isomer sequence
and obtained from New England Peptide, Inc. Autophagy-
inducing peptides loaded lipid-coated PLGA nanoparticles
were synthesized using single step nanoprecipitation. Poly
(D,L-lactic-co-glycolic acid) PLGA (50:50, 0.67 dl/g, Pelham,
AL) with ester-terminated and autophagy-inducing peptides
were dissolved in organic solvent acetonitrile at 10mg/ml.
Soybean lecithin and DSPE-PEG2000-COOH (1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-carboxy (polyenylene
glycol)2000) (Alabaster, AL) was mixed in chloroform at
20% of the PLGA polymer weight and air-dried as a lipid
film. The dissolved PLGA/autophagy-inducing peptides
organic solution was added into the lipid film under gentle
stirring and further vortexed for 3min. PLGA nanoparticles
were then washed with 10mM tris-HCl pH 8 buffer and
loaded with autophagy-inducing peptides. The remaining
acetonitrile and free polymers were removed by washing
using an Amicon Ultra-4 centrifugal filter (Millipore, Bill-
erica, MA) with a molecular weight cut-off of 10 kDa.
Characterization of NP-Beclin 1 and NP-vFLIP-α2
The morphological characteristics of NP-Beclin 1 and
NP-vFLIP-α2 were evaluated by JEOL Gatan transmission
electron microscopy (TEM) using negative staining. The
size, polydispersity index and surface zeta potential were
measured by dynamic light scattering Malvern Zetasizer
Nano ZS for each of nanoformulations. The peptide
loading capacity was evaluated by Slide-A-Yzer MINI
dialysis microtube with a molecular weight cutoff of
3.5 kDa (Thermofisher, Rockford, IL), and determined by
the weight ratio of the peptide payload to the PLGA
nanoparticles.
Generation of HIV latently infected primary resting
memory CD4+ T cells
HIV latently infected resting memory T cells were
generated following our previously published protocol34.
Briefly, resting memory CD4+ T cells from HIV-
uninfected donors were suspended with RPMI 1640
medium with 10% fetal bovine serum supplemented with
29 nM CCL19 (PeproTech, Rocky Hill, NJ) for 48 h. Next,
the CD4+ T cells were infected with HIVNL4-3 at a mul-
tiplicity of infection (M.O.I.) of 0.1, and incubated with
250 ng/mL staphylococcal enterotoxin B (Sigma, St.Louis,
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MO) and 25 U/mL IL-2 (Roche, Basel, Switzerland) for an
additional 3 days. After removal of staphylococcal enter-
otoxin, cells were cultured with 25 U/mL IL-2 for another
9 days. Then, the central memory CD4+ T cells were
purified from HIV-infected CD4+ T cells using negative
magnetic isolation, and further cultured with 1 ng/mL IL-
7 (PeproTech, Rocky Hill, NJ), 100 nM atazanavir and
200 nM tenofovir (Selleckchem, Houston, TX) for another
20 days.
Quantitative viral out growth assay of HIV latent ex vivo
CD4+ T in the isolated patient blood
Our laboratory has adapted the Quantitative viral out
growth assay (QVOA) assay previously established by the
Siliciano laboratory34,70. HIV-infected patients who were
virologically suppressed on ART, had a viral load of <20
copies/mL for at least 12 months and had a CD4+ count
of >400 cells/mm3 were recruited and obtained informed
consent at University of California San Diego Mother-
Child-Adolescent HIV Program clinic, and Peripheral
blood mononuclear cells (PBMC) were isolated from
collected venous blood using Ficoo-PaqueTM density
centrifugation (GE Healthcare, Pittsburgh, PA). Resting
CD4+ T cells were purified through negative magnetic
cell isolation of human CD25, CD69 and anti-HLA-DR
following the manufacturer’s protocols, and reactivated
with gamma irradiation (5000R in Cs-source) and phy-
tohemagglutinin (PHA-M, 1 μg/mL). The CD8+ T cell
depleted PBMC were reactivated with PHA-M and used
as feeder cells to co-culture with limiting dilution of
resting CD4+ T cells for 3 weeks. The collected cell cul-
tured supernatants were tested with HIV p24 antigen
using by ELISA.
Western blotting
The collected cell lysates were mixed with pierce lane
marker reducing sample buffer (ThermoFisher Scientific,
Waltham, MA) and boiled for 5 min to achieve protein
denaturation. The protein samples were separated by
ExpressPlus PAGE Gels and electrophoretic transferred to
PVDF or nitrocellulose membrane. The targeted proteins
were detected by primary anti-LC3B (Novus Biologicals,
Littleton, CO), anti-ATP1A1, anti-ATG5, anti-ATG7
(Cell Signaling Technology, Danvers, MA) and anti-
SQSTM1 antibodies (Abcam, Cambridge, MA). The
horseradish peroxidase conjugated goat anti-mouse and
anti-rabbit secondary antibodies were used to amplify the
detected antigen.
Cytotoxicity assay
The collected cell culture supernatants were co-
incubated with LDH cytotoxicity assay reaction buffer
following the manufacture’s protocol (Clontech, Moun-
tain View, CA). The colorimetric results were quantified
using a BioTek microplate reader at 490 nm wavelength.
The dead cells were counterstained with 0.4% trypan blue
solution and quantified by Nexcelom cell counter.
TZM-bl HIV infectivity assay
TZM-bl HIV infectivity was tested following an estab-
lished protocol35. Briefly, the collected cell culture
supernatants were loaded into 96-well plates containing
50,000 TZM-bl cells per well in RPMI 1640 medium with
10% FBS, and incubated at 37 °C for 48 h. After washing,
the incubated TZM-bl cells were measured by Beta-Glo
assay kit (Promega, Madison, WI).
Measurement of HIV infection
Genomic DNA from TCM was isolated through the
PureLink® Genomic DNA Kits (Invitrogen, Carlsbad,
CA). Following the established protocol71–73, integrated
viral DNA was measured with Alu-gag QPCR. The iso-
lated genomic DNA from ACH-2 and 8E5 cell lines was
used as HIV standards. The collected cell culture super-
naturants were tested for HIVp24 ELISA (PerkinElmer,
Waltham, MA) and RT activity (ThermoFisher, Carlsbad,
CA) following the manufacture protocol.
RNA interference
Short hairpin RNA lentiviral transduction particles kits
were purchased from Sigma-Aldrich for silencing ATG5,
ATG7 and ATP1A1 in primary central CD4+ T memory
cells (ATG5-TRCN0000151963, ATG7-TRCN0000435480
and ATP1A1-TRCN0000424769). The lentiviral shRNA
were transduced following the manufacture’s protocols.
shRNA control vector was also obtained from Sigma-
Aldrich used as non-specific targeting control (SHC002).
Statistics
All results were assessed in GraphPad Prism 6.0
(GraphPad, La Jolla, CA). The normalized data including
fold and ratio changes were transformed into log2 value to
normalize the data. Two-tailed Student t test, ANOVA,
Pearson correlation and Wilcoxon rank test were applied
for statistical analysis. P values < 0.05 two-tailed were
considered statistically significant.
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